Kymera Therapeutics logo

Kymera Therapeutics

KYMR | NASDAQ
Chart Builder DCF Calculator
$125.85
-$1.72 (-1.35%)
At close: Nov 16, 2026, 4:00 PM ET
$123.50
-$2.35 (-1.87%)
After-hours: Nov 16, 2026, 7:59 PM ET
-1.35%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
28.1
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #853/1021 (Top 84%)

Key Statistics

Market Data

Market Cap $12.6B
1D Range
123.67 128.94
52W Range
64.10 138.86

Valuation (TTM)

PE -34.67
PB 7.80
EV/EBITDA -34.29

Valuation (NTM)

Forward PE N/A
Forward PEG -2.31
Price Target $140.00
Loading financial charts...

Profile

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent prot...

Sector Healthcare
Industry Biotechnology
Employees 273
IPO Date Aug 21, 2020
Fiscal Year January - December

Latest News

Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript

18 days ago · seekingalpha.com

Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Kymera Therapeutics Q3 Earnings Call Highlights

18 days ago · marketbeat.com

Kymera Therapeutics Q3 Earnings Call Highlights
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

19 days ago · globenewswire.com

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

19 days ago · globenewswire.com

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

25 days ago · globenewswire.com

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?

29 days ago · zacks.com

Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · seekingalpha.com

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

2 months ago · zacks.com

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Can KT-621 Mark a Turning Point for Kymera Therapeutics?

2 months ago · zacks.com

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

Earnings

Latest Earnings
Oct 29, 2026
EPS
-$1.32
Miss -4.76%
REV
$1.35M
Miss -58.79%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
22
Consensus
Buy
Price Target
$140.00
Upside
+11.24%
Buy (21)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.